MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy / / by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
(Visualizza in formato marc)
(Visualizza in BIBFRAME)
| Autore: |
Aptsiauri Natalia
|
| Titolo: |
MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy / / by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
|
| Pubblicazione: | New York, NY : , : Springer New York : , : Imprint : Springer, , 2013 |
| Edizione: | 1st ed. 2013. |
| Descrizione fisica: | 1 online resource (51 p.) |
| Disciplina: | 616.99/4079 |
| Soggetto topico: | Cancer research |
| Immunology | |
| Molecular biology | |
| Cancer Research | |
| Molecular Medicine | |
| Persona (resp. second.): | Garcia-LoraAngel Miguel |
| CabreraTeresa | |
| Note generali: | Description based upon print version of record. |
| Nota di contenuto: | Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion. |
| Sommario/riassunto: | Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. . |
| Titolo autorizzato: | MHC Class I Antigens In Malignant Cells |
| ISBN: | 1-4614-6543-5 |
| Formato: | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910437613903321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |
Serie:
SpringerBriefs in Cancer Research, . 2194-1173 ; ; 1